Sanofi Discontinues Autoimmune Drug Program, Nurix Says
Nurix said Sanofi ended development of an experimental treatment for autoimmune and inflammatory diseases, eliminating potential future milestone payments and royalties tied to the program.
Nurix Therapeutics NASDAQ:NRIX said on Tuesday that Sanofi has decided to discontinue development of an experimental treatment for autoimmune and inflammatory diseases, eliminating potential future milestone payments and royalties related to the program.Shares of Nurix plunged 38% in extended tradi…